Supplementary tables: Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

These are peer-reviewed supplementary materials for the article 'Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: PICOS criteria defining the scope of the current SLRSupplementary Table 2: Search strategiesSupplementary table 3: MINORS assessmentsSupplementary table 4: Cochrane Risk of Bias 2 assessmentsAim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). Patients & methods: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. Results: Among 17 included trials, key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these characteristics. Conclusion: Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data.

本数据集为发表于《比较有效性研究杂志》上的文章《复发性或难治性弥漫性大B细胞淋巴瘤的结局与患者异质性的系统综述》的同行评审补充材料。补充表1：定义当前系统综述范围之PICOS标准；补充表2：检索策略；补充表3：MINORS评估；补充表4：Cochrane偏倚风险2级评估。研究目的：评估移植不适宜或已移植经验、复发性/难治性弥漫性大B细胞淋巴瘤的系统治疗试验，以及患者特征对总缓解率（ORR）的影响。研究方法：至2021年7月22日系统性地审查了多个数据库。分析了患者特征及其与试验中ORR的关系。研究结果：在17项纳入的试验中，关键患者特征存在显著差异：原发难治性（0–69%），对最后一线治疗方案难治性（12–100%），既往≥2次最后一线治疗方案（14–100%），既往≥3次最后一线治疗方案（0–64%），IPI≥3（23–73%），肿瘤分期III/IV期（50–90%），中位年龄（56–74岁）。ORR存在显著差异（25–83%），与这些特征相关。研究结论：患者特征的差异显著影响了这些试验中ORR的变异性，在解释疗效数据时应予以考虑。